
Marcos Gonzalez DÃ-az

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/783388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	2.5	7
2	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	5.2	42
3	Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. Molecular Cancer, 2022, 21, 35.	19.2	11
4	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. International Journal of Molecular Sciences, 2022, 23, 5570.	4.1	14
5	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. Blood Cancer Journal, 2021, 11, 11.	6.2	3
6	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia, 2021, 35, 2358-2370.	7.2	31
7	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood, 2021, 138, 1830-1842.	1.4	40
8	Liquid biopsy: a nonâ€invasive approach for Hodgkin lymphoma genotyping. British Journal of Haematology, 2021, 195, 542-551.	2.5	14
9	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 and -DQA1 in Castile and Leon region from North West of Spain. Human Immunology, 2021, 82, 549-550.	2.4	1
10	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). PLoS ONE, 2021, 16, e0257353.	2.5	1
11	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Annals of Hematology, 2021, 100, 825-830.	1.8	2
12	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. Frontiers in Oncology, 2021, 11, 723722.	2.8	0
13	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. European Journal of Haematology, 2020, 104, 162-169.	2.2	6
14	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	6.2	60
15	Identification of relapseâ€associated gene mutations by nextâ€generation sequencing in lowâ€risk acute myeloid leukaemia patients. British Journal of Haematology, 2020, 189, 718-730.	2.5	12
16	Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma. Cancers, 2020, 12, 474.	3.7	10
17	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	1.4	24
18	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. Blood Cancer Journal, 2019, 9, 52.	6.2	11

Marcos Gonzalez DÃaz

#	Article	IF	CITATIONS
19	Life expectancy of follicular lymphoma patients in complete response at 30Âmonths is similar to that of the Spanish general population. British Journal of Haematology, 2019, 185, 480-491.	2.5	26
20	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	1.4	66
21	Exportinâ€1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. Hematological Oncology, 2019, 37, 215-218.	1.7	2
22	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica, 2019, 104, 576-586.	3.5	40
23	Richter transformation driven by Epstein–Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	4.5	24
24	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica, 2018, 103, 1198-1208.	3.5	34
25	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Modern Pathology, 2018, 31, 1318-1331.	5.5	9
26	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 633-642.	1.3	8
27	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2318-2326.	1.3	5
28	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. Cancers, 2018, 10, 436.	3.7	8
29	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Advances, 2018, 2, 1719-1737.	5.2	25
30	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia, 2018, 32, 2701-2705.	7.2	19
31	A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Oncotarget, 2018, 9, 26019-26031.	1.8	8
32	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 2017, 31, 2094-2103.	7.2	486
33	Actualización de las guÃas nacionales de consenso del Grupo Español de Leucemia LinfocÃŧica Crónica para el tratamiento y seguimiento de la leucemia linfocÃŧica crónica. Medicina ClÃnica, 2017, 148, 381.e1-381.e9.	0.6	2
34	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. Haematologica, 2017, 102, 1238-1246.	3.5	9
35	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2017, 10, 83.	17.0	38
36	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. Biology of Blood and Marrow Transplantation, 2017, 23, 2042-2047.	2.0	13

#	Article	IF	CITATIONS
37	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leukemia and Lymphoma, 2017, 58, 1144-1152.	1.3	28
38	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. Thrombosis and Haemostasis, 2017, 117, 66-74.	3.4	36
39	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. PLoS ONE, 2017, 12, e0172978.	2.5	4
40	Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis. PLoS ONE, 2017, 12, e0182470.	2.5	19
41	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i> aberrations. Oncotarget, 2016, 7, 80916-80924.	1.8	29
42	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. PLoS ONE, 2016, 11, e0146722.	2.5	70
43	Design and application of a 23â€gene panel by nextâ€generation sequencing for inherited coagulation bleeding disorders. Haemophilia, 2016, 22, 590-597.	2.1	43
44	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematological Oncology, 2016, 34, 84-92.	1.7	26
45	Multipronged functional proteomics approaches for global identification of altered cell signalling pathways in Bâ€cell chronic lymphocytic leukaemia. Proteomics, 2016, 16, 1193-1203.	2.2	15
46	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	12.8	42
47	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. Leukemia Research, 2016, 46, 30-36.	0.8	8
48	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 2122-2130.	1.4	260
49	Origin of Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 136-147.	1.7	17
50	Sarcoma histiocÃtico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfoide B. Revista Espanola De Patologia, 2016, 49, 254-258.	0.2	0
51	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. Annals of Hematology, 2016, 95, 253-262.	1.8	19
52	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia Research, 2016, 40, 1-9.	0.8	29
53	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. Blood, 2016, 128, 375-375.	1.4	1
54	Detection of chromothripsisâ€like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2015, 54, 668-680.	2.8	23

#	Article	IF	CITATIONS
55	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase lb/II panobidara study. Haematologica, 2015, 100, 1294-1300.	3.5	27
56	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica, 2015, 100, e183-e185.	3.5	20
57	The Genotype of the Donor for the (CT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS ONE, 2015, 10, e0140454.	2.5	11
58	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2015, 10, e0143073.	2.5	24
59	Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles. Leukemia Research, 2015, 39, 921-924.	0.8	12
60	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. Annals of Hematology, 2015, 94, 609-616.	1.8	7
61	Subjects with chronic lymphocytic leukaemiaâ€like <scp>B</scp> â€cell clones with stereotyped <scp>B</scp> â€cell receptors frequently show <scp>MDS</scp> â€associated phenotypes on myeloid cells. British Journal of Haematology, 2015, 168, 258-267.	2.5	5
62	Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. Bone Marrow Transplantation, 2015, 50, 298-300.	2.4	1
63	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	27.8	749
64	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia, 2015, 29, 1435-1437.	7.2	17
65	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	2.6	16
66	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia, 2015, 29, 598-605.	7.2	129
67	<scp>CXCR4</scp> expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. Journal of Pathology, 2015, 235, 445-455.	4.5	71
68	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. Cell Cycle, 2014, 13, 1717-1726.	2.6	7
69	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99, 155-162.	3.5	23
70	Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders. Haematologica, 2014, 99, 897-907.	3.5	22
71	Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. Hematology Reports, 2014, 6, 5654.	0.8	4
72	<i>TET2</i> Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence of <i>TET2</i> Variations. BioMed Research International, 2014, 2014, 1-6.	1.9	12

#	Article	IF	CITATIONS
73	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 768-773.	1.2	28
74	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia, 2014, 28, 391-397.	7.2	155
75	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia Research, 2014, 38, 551-556.	0.8	11
76	Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leukemia and Lymphoma, 2014, 55, 1007-1012.	1.3	20
77	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796.	1.4	97
78	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 2014, 99, e231-e234.	3.5	33
79	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380
80	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Annals of Hematology, 2013, 92, 97-100.	1.8	18
81	Pediatric Primary Follicular Mucinosis: Further Evidence of its Relationship with Mycosis Fungoides. Pediatric Dermatology, 2013, 30, e218-20.	0.9	10
82	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genetics, 2013, 206, 49-62.	0.4	63
83	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia, 2013, 27, 1100-1106.	7.2	167
84	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia, 2013, 27, 1722-1728.	7.2	238
85	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Annals of Hematology, 2013, 92, 1151-1179.	1.8	22
86	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood, 2013, 122, 3951-3959.	1.4	55
87	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. British Journal of Haematology, 2013, 163, 223-234.	2.5	7
88	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood, 2013, 122, 1448-1454.	1.4	23
89	Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e67751.	2.5	27
90	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia, 2012, 26, 2521-2529.	7.2	100

#	Article	IF	CITATIONS
91	Expression of <i>MALT1</i> oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10534-10539.	7.1	73
92	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica, 2012, 97, 1218-1224.	3.5	83
93	Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14. PLoS ONE, 2012, 7, e48485.	2.5	37
94	Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Annals of Oncology, 2012, 23, 2138-2146.	1.2	13
95	Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2012, 181, 1879-1888.	3.8	31
96	Multiple cranial neuropathy and intracranial hypertension associated with all-trans retinoic acid treatment in a young adult patient with acute promyelocytic leukemia. International Journal of Hematology, 2012, 96, 383-385.	1.6	10
97	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. Leukemia, 2012, 26, 2360-2366.	7.2	55
98	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 47-52.	21.4	893
99	The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia, 2012, 26, 1821-1828.	7.2	83
100	Risk of placentaâ€mediated pregnancy complications or pregnancyâ€related <scp>VTE</scp> in <scp>VTE</scp> â€asymptomatic families of probands with <scp>VTE</scp> and heterozygosity for factor V <scp>L</scp> eiden or <scp>G</scp> 20210 prothrombin mutation. European Journal of Haematology, 2012, 89, 250-255.	2.2	5
101	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. British Journal of Haematology, 2012, 157, 67-74.	2.5	39
102	Common Infectious Agents and Monoclonal B-Cell Lymphocytosis: A Cross-Sectional Epidemiological Study among Healthy Adults. PLoS ONE, 2012, 7, e52808.	2.5	32
103	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	27.8	1,364
104	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 2011, 96, 468-471.	3.5	29
105	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 2011, 96, 1470-1477.	3.5	59
106	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood, 2011, 117, 1799-1805.	1.4	112
107	Frequency of HLAâ€A, â€B and â€DRB1 specificities and haplotypic associations in the population of Castilla y León (northwestâ€central Spain). Tissue Antigens, 2011, 78, 249-255.	1.0	14
108	Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation. Annals of Hematology, 2011, 90, 227-229.	1.8	1

#	Article	IF	CITATIONS
109	Molecular and flow cytometry characterization during the followâ€up of three simultaneous lymphoproliferative disorders: Hairy cell leukemia, monoclonal Bâ€cell lymphocytosis, and CD4 ⁺⁺ /CD8 ^{+/â°dim} Tâ€large granular lymphocytosis—A case report. Cytometry Part B - Clinical Cytometry, 2011, 80B, 195-200.	1.5	6
110	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica, 2010, 95, 1317-1324.	3.5	53
111	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood, 2010, 116, 5650-5659.	1.4	33
112	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica, 2010, 95, 424-431.	3.5	84
113	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Annals of Hematology, 2010, 89, 453-458.	1.8	40
114	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 2010, 24, 629-637.	7.2	188
115	International network of cancer genome projects. Nature, 2010, 464, 993-998.	27.8	2,114
116	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica, 2010, 95, 87-95.	3.5	164
117	Long FLT3 internal tandem duplications and reduced PML-RARÂ expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica, 2010, 95, 745-751.	3.5	47
118	Mapping of Genetic Abnormalities of Primary Tumours from Metastatic CRC by High-Resolution SNP Arrays. PLoS ONE, 2010, 5, e13752.	2.5	22
119	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 4578-4584.	1.6	116
120	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B ell lymphomas. Cancer, 2009, 115, 3728-3737.	4.1	31
121	Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. Leukemia Research, 2009, 33, e20-e22.	0.8	5
122	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leukemia Research, 2009, 33, 1706-1709.	0.8	49
123	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica, 2009, 94, 364-371.	3.5	59
124	Influence of <i>MBL-2</i> mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. Leukemia and Lymphoma, 2009, 50, 1283-1289.	1.3	6
125	Molecular and Epidemiologic Findings of Childhood Acute Leukemia in Costa Rica. Journal of Pediatric Hematology/Oncology, 2009, 31, 131-135.	0.6	12
126	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica, 2009, 94, 1242-1249.	3.5	93

#	Article	IF	CITATIONS
127	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood, 2009, 113, 775-783.	1.4	279
128	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood, 2009, 114, 148-152.	1.4	78
129	Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood, 2009, 114, 33-37.	1.4	183
130	Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Laboratory Investigation, 2008, 88, 306-317.	3.7	11
131	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens, 2008, 71, 548-551.	1.0	3
132	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. British Journal of Haematology, 2008, 141, 212-215.	2.5	29
133	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. British Journal of Haematology, 2008, 142, 529-537.	2.5	78
134	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clinical Cancer Research, 2008, 14, 155-161.	7.0	117
135	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008, 111, 3395-3402.	1.4	303
136	Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood, 2008, 111, 5130-5141.	1.4	22
137	Expanded cells in monoclonal TCR-αβ+/CD4+/NKa+/CD8â^'/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood, 2008, 112, 4609-4616.	1.4	54
138	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	1.4	154
139	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood, 2008, 112, 2709-2712.	1.4	213
140	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica, 2008, 93, 1797-1805.	3.5	41
141	Clinical and Prognostic Value of Discrepancies in Microsatellite DNA Regions Between Recipient and Donor in Human Leukocyte Antigen-Identical Allogeneic Transplantation Setting. Transplantation, 2008, 86, 983-990.	1.0	4
142	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica, 2007, 92, 635-642.	3.5	57
143	Monoclonal TCR-Vβ13.1+/CD4+/NKa+/CD8â^'/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood, 2007, 109, 4890-4898.	1.4	72
144	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood, 2007, 109, 4258-4263.	1.4	104

Marcos Gonzalez DÃaz

#	Article	IF	CITATIONS
145	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors Blood, 2007, 110, 461-467.	1.4	82
146	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood, 2007, 110, 3112-3121.	1.4	157
147	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. Thrombosis Research, 2007, 119, 691-698.	1.7	7
148	Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia. Clinical Lymphoma and Myeloma, 2007, 7, 573-579.	1.4	9
149	Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia, 2007, 21, 446-452.	7.2	124
150	Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia, 2007, 21, 1413-1422.	7.2	45
151	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia, 2007, 21, 1481-1487.	7.2	29
152	Functional class switch recombination may occur â€~in vivo' in Waldenström macroglobulinaemia. British Journal of Haematology, 2007, 136, 114-116.	2.5	18
153	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British Journal of Haematology, 2007, 136, 590-596.	2.5	75
154	Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. British Journal of Haematology, 2006, 135, 43-51.	2.5	25
155	TCRÎ ³ δ+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRÎ ³ δ+ T-cells. Leukemia, 2006, 20, 505-513.	7.2	86
156	The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia. Hematological Oncology, 2006, 9, 33-42.	1.7	7
157	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols Blood, 2006, 108, 1503-1503.	1.4	19
158	The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. Haematologica, 2006, 91, 1551-4.	3.5	11
159	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia, 2005, 19, 402-409.	7.2	85
160	Treatment With All- <i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. Journal of Clinical Oncology, 2005, 23, 7632-7640.	1.6	126
161	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. Haematologica, 2005, 90, 906-13.	3.5	20
162	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica, 2005, 90, 1365-72.	3.5	135

#	Article	IF	CITATIONS
163	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. The Hematology Journal, 2004, 5, 239-246.	1.4	37
164	Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. Clinical Chemistry, 2004, 50, 1088-1092.	3.2	8
165	Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease – a study within the Europe Against Cancer Program. Leukemia, 2004, 18, 884-886.	7.2	40
166	HLA-DPB1 MISMATCH IN HLA-A-B-DRB1 IDENTICAL SIBLING DONOR STEM CELL TRANSPLANTATION AND ACUTE GRAFT-VERSUS-HOST DISEASE. Transplantation, 2004, 77, 1107-1110.	1.0	23
167	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols Blood, 2004, 104, 2019-2019.	1.4	5
168	Identification and Characterization of Single Nucleotide Polymorphisms (SNPs) Associated with Genetic Predisposition to Develop Therapy-Related Acute Myeloid Leukemia (t-AML) Blood, 2004, 104, 3001-3001.	1.4	0
169	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. Leukemia, 2003, 17, 1051-1057.	7.2	27
170	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. Leukemia, 2003, 17, 1398-1403.	7.2	38
171	Standardization and quality control studies of â€real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia, 2003, 17, 2318-2357.	7.2	1,359
172	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003, 17, 2257-2317.	7.2	2,788
173	TCRαβ+/CD4+ Large Granular Lymphocytosis. American Journal of Pathology, 2003, 163, 763-771.	3.8	104
174	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	1.4	395
175	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	1.4	121
176	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood, 2003, 102, 2994-3002.	1.4	101
177	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. British Journal of Haematology, 2002, 117, 890-892.	2.5	24
178	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. British Journal of Haematology, 2002, 118, 239-242.	2.5	54
179	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. British Journal of Haematology, 2002, 118, 1034-1040.	2.5	76
180	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in softâ€tissue plasmacytomas. British Journal of Haematology, 2002, 119, 883-884.	2.5	12

#	Article	IF	CITATIONS
181	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia, 2002, 16, 1423-1431.	7.2	103
182	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 2001, 98, 1746-1751.	1.4	316
183	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the <i>PMLâ€RARα</i> isoforms: a study of the PETHEMA group. British Journal of Haematology, 2001, 114, 99-103.	2.5	52
184	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyt. British Journal of Haematology, 2001, 114, 931-936.	2.5	60
185	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 665-672.	2.4	14
186	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. Leukemia, 2001, 15, 121-127.	7.2	20
187	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia, 2001, 15, 406-414.	7.2	94
188	Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia, 2001, 15, 840-845.	7.2	50
189	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. The Hematology Journal, 2001, 2, 146-149.	1.4	30
190	Two new 3?PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
191	Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. British Journal of Haematology, 2000, 109, 658-660.	2.5	18
192	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. Clinical Biochemistry, 2000, 33, 415-418.	1.9	5
193	Two new 3′ PML Breakpoints in t(15;17)(q22;q21)â€positive acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2000, 27, 35-43.	2.8	3
194	Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 1998, 9, 849-855.	1.2	264
195	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Annals of Hematology, 1997, 74, 79-82.	1.8	10
196	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. British Journal of Haematology, 1996, 93, 81-88.	2.5	69
197	Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. British Journal of Haematology, 1995, 89, 104-109.	2.5	24
198	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. British Journal of Haematology, 1995, 90, 106-112.	2.5	74

#	Article	IF	CITATIONS
199	3Immunophenotype and DNA cell content in multiple myeloma. Best Practice and Research: Clinical Haematology, 1995, 8, 735-759.	1.1	54
200	Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. Cytometry, 1995, 22, 217-222.	1.8	24
201	Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology, 1995, 70, 189-194.	1.8	73
202	The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. Annals of Hematology, 1994, 68, 233-236.	1.8	3
203	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry, 1994, 17, 332-339.	1.8	68
204	Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences. American Journal of Hematology, 1993, 43, 256-258.	4.1	8
205	Immunological features of sporadic multinodular goiter. The Clinical Investigator, 1993, 71, 552-8.	0.6	13
206	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. British Journal of Cancer, 1993, 68, 1227-1231.	6.4	45
207	Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. Annals of Hematology, 1993, 67, 217-222.	1.8	35
208	Immunoblastic lymphoma and associated nonâ€lymphoid malignancies following two cases of WaldenstrA¶m's macroglobulinemia. A review of the literature. European Journal of Haematology, 1993, 50, 299-301.	2.2	15
209	Longâ€ŧerm treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. British Journal of Haematology, 1992, 82, 671-675.	2.5	22
210	Lymphoid subsets and prognostic factors in multiple myeloma. British Journal of Haematology, 1992, 80, 305-309.	2.5	64
211	Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. European Journal of Cancer & Clinical Oncology, 1991, 27, S48-S49.	0.7	3
212	Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. British Journal of Haematology, 1991, 79, 408-414.	2.5	33
213	Combination of interferon and dexamethasone in refractory multiple myeloma. Hematological Oncology, 1990, 8, 185-189.	1.7	20
214	B-cell chronic lymphocytic leukaemia: Prognostic value of the immunophenotype and the clinico-haematological features. American Journal of Hematology, 1989, 31, 26-31.	4.1	28
215	Prognostic factors and classification in multiple myeloma. British Journal of Cancer, 1989, 59, 113-118.	6.4	50
216	Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia. Blut, 1988, 57, 19-23.	1.2	4

#	Article	IF	CITATIONS
217	Skin involvement in non-secretory myeloma. American Journal of Medicine, 1988, 84, 373-374.	1.5	3
218	Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. Clinical Immunology and Immunopathology, 1988, 46, 177-185.	2.0	13
219	Discrepancies Between Morphologic, Cytochemical, and Immunologic Characteristics in Acute Myeloblastic Leukemia. American Journal of Clinical Pathology, 1987, 88, 38-42.	0.7	17
220	Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. European Journal of Cancer & Clinical Oncology, 1987, 23, 1417-1418.	0.7	0
221	Letter to the editor: T-cell subsets and myeloma cell mass. American Journal of Hematology, 1987, 25, 235-236.	4.1	3
222	PLASMABLASTIC MULTIPLE MYELOMA: AN IMMUNOLOGICALLY DIFFERENT SUBTYPE. British Journal of Haematology, 1987, 66, 275-281.	2.5	4
223	TdT activity in acute myeloid leukemias defined by monoclonal antibodies. American Journal of Hematology, 1986, 23, 9-17.	4.1	13
224	Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. British Journal of Haematology, 1986, 64, 547-560.	2.5	108
225	Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. British Journal of Haematology, 1986, 62, 75-83.	2.5	51
226	Coexpression of T―and Bâ€markers in a lymphoproliferative disorder. Scandinavian Journal of Haematology, 1986, 37, 10-17.	0.0	4
227	CYTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF MONOCLONAL GAMMOPATHIES. British Journal of Haematology, 1985, 60, 768-769.	2.5	4
228	T-cell subpopulations in patients with monoclonal gammopathies: Essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. American Journal of Hematology, 1985, 20, 267-273.	4.1	24
229	Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. Clinical Immunology and Immunopathology, 1985, 35, 139-145.	2.0	1
230	HELPER/SUPPRESSOR T-CELL SUBPOPULATIONS IN BENIGN PARAPROTEINAEMIA. British Journal of Haematology, 1983, 54, 318-320.	2.5	6